Marina Frimer, MD, Talks Future Treatments in Uterine Cancer

Video

Marina Frimer, MD, spoke about what the future holds for the treatment of patients with platinum-sensitive recurrent uterine cancer.

At The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, CancerNetwork® spoke with Marina Frimer, MD, associate chief of Research & Academic Development Central Region, and associate professor at the Donald and Barbara Zucker School of Medicine at Hofsta/Nortwell Health in New Hyde Park, New York, about recruiting patients to a trial (NCT04080284) examining maintenance niraparib (Zejula) for platinum-sensitive recurrent uterine cancer.

Transcript:

For [patients with] uterine serous cancer, we have an option for trastuzumab [Herceptin] in women who have a HER2 mutation. However, in women who don’t [harbor a mutation we don’t] have any other maintenance therapy options available at this time. For those patients, we are able to discuss the trial participation.

We really want to open this trial so that other [clinicians can send patients who] may potentially fit the criteria. Given the rarity of the tumor type, it’s very difficult to recruit patients to this trial. We’re really hoping to increase our publicity at the meeting.

Reference

Frimer M, Nizam A, Sison C, et al. Phase II trial of maintenance niraparib in patients with stage III, stage IV or platinum-sensitive recurrent uterine serous carcinoma. Presented at: 2022 SGO Annual Meeting on Women’s Cancer; March 18-21, 2022. Phoenix, Arizona.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content